April 2020 HSC Section 4 - Plastic and Reconstructive Problems

Sanniec K, Afrooz PN, Burns AJ. Long-term assessment of perioral rhytide correction with erbium:YAG laser resurfacing. Plast Reconstr Surg . 2019; 143(1):64-74. EBM level 4................40-50

Summary : The authors describe their long-term outcomes in patients receiving erbium:YAG rejuvenation of the perioral region. This is more a case-series, but the value lies in the in-depth explanation of the physics of the erbium:YAG laser and the authors’ preferred technique.

D. Injectables and chemodenervation Bertossi D, Giampaoli G, Verner I, et al. Complications and management after a nonsurgical rhinoplasty: a literature review. Dermatol Ther . 2019; 32(4):e12978. EBM level N/A...................51-58

Summary : Early recognition of minor and major complications in nonsurgical (filler) rhinoplasty is important.

Glogau RG, Glaser DA, Callender VD, et al. A double-blind, placebo-controlled, phase 3b study of ATX-101 for reduction of mild or extreme submental fat. Dermatol Surg . 2019; 45(12):1531-1541. EBM level 1.........................................................................................................................................59-69

Summary : ATX-101 (Kybella) was well tolerated and efficacious at reducing mild to extreme submental fat.

E. Blepharoplasty Zoumalan CI, Roostaeian J. Simplifying blepharoplasty. Plast Reconstr Surg . 2016; 137(1):196e- 213e. EBM level 5...............................................................................................................................70-87

Summary : The authors describe an algorithm for approaching upper and lower lid blepharoplasty. Indications and complications are discussed.

F. Hair restoration Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol . 2017; 77(1):136-141. EBM level 1.......................................88-98 Summary : The only treatments recognized by the FDA for androgenetic alopecia (AGA) are minoxidil and finasteride (both FDA-approved) and low-level laser light therapy (FDA-cleared). This study is a systematic review of randomized controlled trials. This meta-analysis suggests that minoxidil, finasteride, and low-level laser light therapy are effective for promoting hair growth in men with AGA, and that minoxidil is effective in women with AGA.

Mao G, Zhang G, Fan W. Platelet-rich plasma for treating androgenic alopecia: a systematic review. Aesthetic Plast Surg . 2019; 43(5):1326-1336. EBM level 3............................................................99-109

Summary: Androgenic alopecia (AGA) is the most common type of hair loss, and infiltration of subcutaneous platelet-rich plasma (PRP) has been suggested to improve AGA. While numerous heterogenous studies evaluate the efficacy of PRP to treat AGA, the authors evaluated the body of literature effectively. Most studies were with small sample size and were non-RCT. Results suggest PRP may be effective in treating AGA.